COCRYSTAL PHARMA, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
COCRYSTAL PHARMA, INC. (COCP) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $79.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-05-15
- COCRYSTAL PHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $79.00K, a 6.76% increase year-over-year.
- COCRYSTAL PHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $74.00K.
- COCRYSTAL PHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-09-30 was $55.00K, a 7.84% increase year-over-year.
- COCRYSTAL PHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-06-30 was $54.00K, a 5.88% increase year-over-year.
- COCRYSTAL PHARMA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $592.00K, a 52.58% increase from fiscal 2021.
- COCRYSTAL PHARMA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $388.00K, a 26.38% decline from fiscal 2020.
- COCRYSTAL PHARMA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $527.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $79.00K 10-Q · filed 2026-05-15 | ||||
| 2025-09-30 | $226.00K 10-Q · filed 2025-11-14 | ||||
| 2025-03-31 | $74.00K 10-Q · filed 2026-05-15 | ||||
| 2024-09-30 | $247.00K 10-Q · filed 2025-11-14 | ||||
| 2023-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $109.00K derived: sum of 2 quarters · filed 2024-11-13 | $163.00K 10-Q · filed 2024-11-13 | $604.00K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $108.00K 10-Q · filed 2023-08-14 | $549.00K derived: sum of 3 quarters · filed 2023-08-14 | $600.00K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2023-03-31 | $54.00K 10-Q · filed 2023-05-15 | $495.00K derived: sum of 2 quarters · filed 2023-05-15 | $546.00K derived: sum of 3 quarters · filed 2023-11-13 | $597.00K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-12-31 | $441.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $492.00K derived: sum of 2 quarters · filed 2023-11-13 | $543.00K derived: sum of 3 quarters · filed 2023-11-13 | $592.00K 10-K · filed 2023-03-29 | |
| 2022-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $102.00K derived: sum of 2 quarters · filed 2023-11-13 | $151.00K 10-Q · filed 2023-11-13 | $396.00K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $100.00K 10-Q · filed 2023-08-14 | $345.00K derived: sum of 3 quarters · filed 2023-08-14 | $393.00K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $49.00K 10-Q · filed 2023-05-15 | $294.00K derived: sum of 2 quarters · filed 2023-05-15 | $342.00K derived: sum of 3 quarters · filed 2023-05-15 | $390.00K derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $245.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $293.00K derived: sum of 2 quarters · filed 2023-03-29 | $341.00K derived: sum of 3 quarters · filed 2023-03-29 | $388.00K 10-K · filed 2023-03-29 | $527.00K 10-K · filed 2022-03-23 |
| 2021-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $96.00K derived: sum of 2 quarters · filed 2022-11-14 | $143.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $95.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $47.00K 10-Q · filed 2022-05-11 | ||||
| 2020-12-31 | $527.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |